Entering text into the input field will update the search result below

Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate

Genetic manipulation and DNA modification concept.

vchal

  • MaxCyte (NASDAQ:MXCT) has signed a non-exclusive licensing deal with Vertex Pharmaceuticals (NASDAQ:VRTX) allowing the latter to use MaxCyte's (MXCT) Flow Electroporation technology and ExPERT™ platform to develop gene-edited therapy exa-cel, previously known as CTX001.
  • Exact financial terms were not disclosed.
  • Exa-cel is an investigational ex vivo CRISPR/Cas-9 gene-edited cell therapy under investigation for transfusion-dependent beta thalassemia or sickle cell disease.
  • MaxCyte's (MXCT) technology was also used in an agreement between the company and CRISPR Therapeutics (CRSP). Vertex is developing exa-cel, currently in phase 2/3, with CRISPR (CRSP).
  • Seeking Alpha's Quant Rating views MaxCyte as a hold with high marks for growth and momentum.

Recommended For You

Related Stocks

SymbolLast Price% Chg
VRTX
--
MXCT
--